Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R.

J Neural Transm (Vienna). 2012 Nov;119(11):1367-71. doi: 10.1007/s00702-012-0796-9. Epub 2012 Mar 22.

PMID:
22437202
2.

[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].

Maurel F, Lilliu H, Le Pen C.

Rev Neurol (Paris). 2001 May;157(5):507-14. French.

PMID:
11438770
3.

The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.

Zhang YH, Tang BS, Song CY, Xu Q, Lou MX, Liu ZH, Yu RH, Yan XX, Guo JF.

Neurosci Lett. 2013 Nov 27;556:109-12. doi: 10.1016/j.neulet.2013.10.018. Epub 2013 Oct 14.

PMID:
24135335
4.

Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; Parkinson Study Group.

Mov Disord. 2004 Jan;19(1):22-8.

PMID:
14743356
5.

Why are some Parkinson disease patients unaware of their dyskinesias?

Jenkinson PM, Edelstyn NM, Stephens R, Ellis SJ.

Cogn Behav Neurol. 2009 Jun;22(2):117-21. doi: 10.1097/WNN.0b013e3181a722b0.

PMID:
19506428
6.

Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.

Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ.

J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):295-7.

7.

Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.

Merims D, Ziv I, Djaldetti R, Melamed E.

Lancet. 1999 May 22;353(9166):1764-5. No abstract available.

PMID:
10347995
8.

Force overflow and levodopa-induced dyskinesias in Parkinson's disease.

Wenzelburger R, Zhang BR, Pohle S, Klebe S, Lorenz D, Herzog J, Wilms H, Deuschl G, Krack P.

Brain. 2002 Apr;125(Pt 4):871-9.

PMID:
11912119
9.

Early morning off-medication dyskinesias, dystonia, and choreic subtypes.

Cubo E, Gracies JM, Benabou R, Olanow CW, Raman R, Leurgans S, Goetz CG.

Arch Neurol. 2001 Sep;58(9):1379-82.

PMID:
11559308
10.

Abnormal bidirectional plasticity-like effects in Parkinson's disease.

Huang YZ, Rothwell JC, Lu CS, Chuang WL, Chen RS.

Brain. 2011 Aug;134(Pt 8):2312-20. doi: 10.1093/brain/awr158. Epub 2011 Jul 8.

PMID:
21742734
11.

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA.

Mov Disord. 2005 Sep;20(9):1205-9.

PMID:
15954135
12.

Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.

Alonso-Frech F, Zamarbide I, Alegre M, Rodríguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA.

Brain. 2006 Jul;129(Pt 7):1748-57. Epub 2006 May 9.

PMID:
16684788
13.

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.

Jankovic J.

Mov Disord. 2005;20 Suppl 11:S11-6. Review.

PMID:
15822109
14.

Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.

Mov Disord. 2005 Mar;20(3):342-4.

PMID:
15580606
15.

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.

Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV.

Parkinsonism Relat Disord. 2012 May;18(4):370-6. doi: 10.1016/j.parkreldis.2011.12.006. Epub 2012 Feb 7.

PMID:
22316635
16.

[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].

Rocha MS, Andrade LA, Ferraz HB, Borges V.

Arq Neuropsiquiatr. 1995 Dec;53(4):737-42. Portuguese.

PMID:
8729765
17.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
18.

Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.

Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.

J Clin Neurosci. 2009 Aug;16(8):1034-7. doi: 10.1016/j.jocn.2008.10.015. Epub 2009 May 9.

PMID:
19428256
19.

High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C.

Clin Neuropharmacol. 2003 May-Jun;26(3):146-50.

PMID:
12782917
20.

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G.

Brain. 2014 Oct;137(Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.

Supplemental Content

Support Center